The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

In terms of vaccines, the Berrien County Health Department recommends everyone 6 months and older get this season’s flu ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Moderna (MRNA) got a boost in the third quarter from an earlier US approval of its updated COVID-19 vaccine, underpinning sales growth and helping drive a surprise net income result at the drugmaker.

In October, the FDA issued the clinical hold due to a spontaneous report ... signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine ...

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Dr. Robert Jacobson, medical director for Mayo Clinic's Primary Care Immunization Program, clears up some misconceptions about COVID-19 and the flu.

Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial ... we started enrollment in our Phase 2b study evaluating our COVID-19 oral pill vaccine candidate against an ...